The Current Ratio as of December 2025 (TTM) for Prostatype Genomics AB (publ) (PROGEN.ST) is 1.95

According to Prostatype Genomics AB (publ)’s latest financial reports and current stock price. The company's current Current Ratio is 1.95. This represents a change of 16.82% compared to the average of 1.67 of the last 4 quarters.

Prostatype Genomics AB (publ) (PROGEN.ST) Historical Current Ratio (quarterly & annually)

How has PROGEN.ST Current Ratio performed in the past?

The mean historical Current Ratio of Prostatype Genomics AB (publ) over the last ten years is 2.97. The current 1.95 Current Ratio has changed 6.48% with respect to the historical average. Over the past ten years (40 quarters), PROGEN.ST's Current Ratio was at its highest in in the September 2021 quarter at 10.01. The Current Ratio was at its lowest in in the March 2024 quarter at 0.17.

Prostatype Genomics AB (publ) (PROGEN.ST) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Prostatype Genomics AB (publ) Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Prostatype Genomics AB (publ) (PROGEN.ST) Average Current Ratio

How has PROGEN.ST Current Ratio performed in the past?

The current Current Ratio of Prostatype Genomics AB (publ) (PROGEN.ST) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Prostatype Genomics AB (publ) (PROGEN.ST) Current Ratio vs. Peers

How is PROGEN.ST’s Current Ratio compared to its peers?

Prostatype Genomics AB (publ)’s Current Ratio is less than Spermosens AB (9.27), greater than Qlife Holding AB (publ) (0.83), less than Episurf Medical AB (publ) (2.75), greater than ODI Pharma AB (1.16), greater than Aptahem AB (publ) (1.72), greater than Aino Health AB (publ) (0.43), greater than Fluicell AB (publ) (1.83), less than 2cureX AB (publ) (2.93), less than Chordate Medical Holding AB (publ) (1.97), less than Stayble Therapeutics AB (publ) (7.18),

Build a custom stock screener for Prostatype Genomics AB (publ) (PROGEN.ST) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Prostatype Genomics AB (publ) using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Prostatype Genomics AB (publ) (PROGEN.ST) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Prostatype Genomics AB (publ) or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.